ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. iZafe Group AB's annualized net income for the quarter that ended in Mar. 2026 was €-2.40 Mil. iZafe Group AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €1.67 Mil. Therefore, iZafe Group AB's annualized ROE % for the quarter that ended in Mar. 2026 was -143.69%.
The historical rank and industry rank for iZafe Group AB's ROE % or its related term are showing as below:
FRA:M02'
s ROE % Range Over the Past 10 Years
Min: -155.76 Med: -99.21 Max: -38.44
Current: -128.25
During the past 13 years, iZafe Group AB's highest ROE % was -38.44%. The lowest was -155.76%. And the median was -99.21%.
FRA:M02's ROE % is ranked worse than 91.61% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs FRA:M02: -128.25
iZafe Group AB (FRA:M02) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
iZafe Group AB ROE % Related Terms
iZafe Group AB ROE % Historical Data
* Premium members only.
The historical data trend for iZafe Group AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, iZafe Group AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iZafe Group AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's ROE % distribution charts can be found below:
* The bar in red indicates where iZafe Group AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
iZafe Group AB (FRA:M02) has a ROE % of -143.69% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on iZafe Group AB and its competitors. According to the industry distribution chart, iZafe Group AB ranks #732 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 91.6%.
Is iZafe Group AB's ROE % too high?
iZafe Group AB's current ROE % is -143.69%. Based on the distribution chart, iZafe Group AB ranks #732 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iZafe Group AB has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iZafe Group AB's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iZafe Group AB ranks #732 out of 799 companies for ROE %. This places iZafe Group AB in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on iZafe Group AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iZafe Group AB's current ROE % is -143.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iZafe Group AB stock overvalued right now?
Based on GuruFocus' analysis, iZafe Group AB (FRA:M02) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.04, compared to a current price of €0.03 — trading 15.5% below its estimated fair value. The current ROE % is -143.69%. iZafe Group AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For iZafe Group AB (FRA:M02), the current ROE % is -143.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iZafe Group AB (FRA:M02) Overvalued in 2026?
Based on GuruFocus' analysis, iZafe Group AB stock appears to be undervalued.
The current stock price of €0.03 is trading 15.5% below its estimated GF Value™ of €0.04.
GuruFocus considers iZafe Group AB to be Modestly Undervalued.
Key valuation signals for FRA:M02:
ROE %: -143.69%
GF Value™: €0.04 vs. price of €0.03 (15.5% below fair value)
No single metric tells the full story. See the FRA:M02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
48GF Score
Get the complete analysis for FRA:M02
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M02 has been successfully added to your 
